3.1. General characteristics
A total of 248 of 301 patients who were admitted to ICU with suspicion of COVID-19 infection were included in the study. Of them, 37 (14.9%) had NOAF (Figure 1). NOAF positive group was older than the NOAF negative group (79.0 [71.5–84.0] vs 70.0 [60.0–78.0] years, p < 0.001; Table 1).
The median duration from the onset of the COVID-19 infection symptoms to NOAF development was 10.0 (5.0–17.0) days. The median duration from hospitalization to NOAF development was 7.0 (2.0–12.5) days, and the median duration from ICU admission to NOAF development was 3.0 (0.0–10.0) days.
Chronic obstructive pulmonary disease (COPD) (24.3% vs. 10.9%, respectively; p = 0.03), and chronic kidney disease (CKD) (27.0%, vs. 13.3%, respectively; p = 0.046) were more common in the NOAF positive group than the NOAF negative group. CCI median score was higher in the NOAF positive group than the NOAF negative group as well (6.0 [5.0–7.0] vs. 4.0 [2.0–6.0], respectively, p = 0.003). NOAF positive group had higher blood urea nitrogen (BUN) than the NOAF negative group median values (37.1 [28.4–75.0] vs. 30.0 [21.0–50.0] mg/dL, respectively, p = 0.003).